Geron Corp. (Nasdaq: GERN) discontinued the 4.7 mg/kg dose arm and suspended enrollment in the 9.4 mg/kg dose arm of imetelstat in a Phase 2 clinical trial. The stock price dropped 56 cents to close at $2.30.
Geron updates Phase 2 imetelstat study
September 12, 2016 at 19:00 PM EDT
